Abstract
OBJECTIVES: This placebo-controlled open study was designed to test the hypothesis that most of the gastrointestinal (GI) side events induced by treatment of obese patients with orlistat (a gastrointestinal lipase inhibitor) could be prevented or ameliorated by concomitant use of natural fibers (psyllium mucilloid).
DESIGN: Two groups of obese women (BMI>27 kg/m2) were treated with orlistat 120 mg three times a day. One group (A, n=30) was randomized to receive orlistat and, approximately 6.0 g of orange-flavored psyllium mucilloid dissolved in water and the other group (B, n=30) received orlistat and orange-flavored placebo. At the end of 30 days and 2 weeks of washout, group A switched to placebo and group B received psyllium while continuing orlistat three times a day.
SUBJECTS: Sixty professional women, more than 21-y-old with a body mass index (BMI) between 27.3 and 48.0 kg/m2, who were not receiving any other medication.
MEASUREMENTS: Assessments included weekly visits to attending physician, filling a form in which GI events were recorded, monthly measurements of body weight, blood pressure and serum lipids. The frequency and severity of GI events were evaluated by a score system, based on information provided by the patients.
RESULTS: Both groups A and B significantly lost (P<0.01) weight after 60 days of orlistat (A=96.8 to 94.9 kg and B=98.7 to 96.5 kg). Similarly, BMI values declined significantly in both groups. While in the psyllium plus orlistat group (group A) the mean ±s.e.m. of the scores reflecting GI events was 13.0±1.8, the placebo plus orlistat group (B) had a value of 35.9±2.7 (P<0.01). When the reverse situation was instituted the placebo and orlistat group presented a mean score of 36.1±3.6 and the psyllium plus orlistat a mean score of 8.9±1.5 (P<0.01).
CONCLUSIONS: Psyllium hydrophilic mucilloid concomitantly prescribed to obese patients receiving 120 mg of orlistat three times a day is an effective and safe adjunct therapy that is helpful in controlling the GI side effects of this pancreatic lipase inhibitor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
James WPT, Avenell A, Broom J, Whitehead J . A one year trial to assess the value of orlistat in the management of obesity Int J Obes Relat Metab Disord 1997 21 (Suppl 3): S24–S30.
Sjöström L, Rissanem A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M . Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients Lancet 1998 352: 167–173.
Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjöström L, van der Veen EA . Orlistat, a lipase inhibitor, in the treatment of human obesity: a multiple dose study Int J Obes Relat Metab Disord l995 19: 221–226.
Davidson MH, Hauptman JB, Digirolamo M, Focyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB . Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat JAMA 1999 281: 235–241.
Bray GA, Greenway FL . Current and potential drugs for treatment of obesity Endocr Rev 1999 20: 805–875.
Hauptman J, Lucas C, Boldrin MN, Collins H, Segall KR . Orlistat in the long-term treatment of obesity in primary care settings Arch Farm Med 2000 9: 160–167.
Everson GT, Daggy BP, McKimley C, Story JA . Effects of psyllium hydrophillic mucilloid on LDL-cholesterol and bile acid synthesis in hypercholesterolemic men J Lipid Res 1992 33: 1183–1192.
Levin EG, Miller VT, Muesing RA, Stoy DB, Balm tK, LaRosa JC . Comparison of psyllium hydrophillic mucilloid and cellulose as adjuncts to a prudent diet in the treatment of mild to moderate hypercholesterolemia Arch Intern Med 1990 150: 1822–1827.
Bell LP, Hectorme K, Reynolds H, Balm TK, Hunninghake DB . Cholesterol-lowering effects of psyllium hydrophilic mucilloid JAMA 1989 261: 3419–3423.
Vahouny GV, Krutchevsky M (eds) . Dietary fiber: basic and clinical aspects Plenum Press: New York 1986 pp 181–209.
Kesaniemi YA, Tarpila S, Miettinem L . Low vs. high dietary fiber and serum, biliary and fecal lipids in middle-aged men Am J Clin Nutr 1990 51: 1007–1012.
Acknowledgements
We acknowledge the help of Creusa R Dal Bó in the statistical analysis of the data. This study was supported by Roche Pharmaceutical Co. and Procter & Gamble (Brazil). The expert secretarial work of Maria Suzette Pott is gratefully acknowledged. Part of this work was reported at the 9th European Congress on Obesity, Milan, Italy (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cavaliere, H., Floriano, I. & Medeiros-Neto, G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes 25, 1095–1099 (2001). https://doi.org/10.1038/sj.ijo.0801645
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801645
Keywords
This article is cited by
-
TC2N inhibits distant metastasis and stemness of breast cancer via blocking fatty acid synthesis
Journal of Translational Medicine (2024)
-
A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption
Experimental & Molecular Medicine (2019)
-
Supplementation with dairy calcium and/or flaxseed fibers in conjunction with orlistat augments fecal fat excretion without altering ratings of gastrointestinal comfort
Nutrition & Metabolism (2017)
-
Inhibitory activity of extracts of Hebridean brown seaweeds on lipase activity
Journal of Applied Phycology (2016)